FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Rebus Holdings, Inc. Stock AnalysisComprehensive stock analysis for Rebus Holdings, Inc. (RBSH) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisRBSH
RBSH
Rebus Holdings, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
RBSH
Home🔹Stocks🔹Rebus Holdings, Inc.

Rebus Holdings, Inc.

🇺🇸RBSH•OTC

Rebus Holdings, Inc.

🇺🇸RBSH•OTC
Market cap
$3.21K
Sentiment

Your view on RBSH

Mkt Cap
$3.21K
Sentiment
Your view
RBSH
Rebus Holdings, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
RBSH
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Rebus Holdings, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Raul Silvestre
Headquarters
2629 Townsgate Road, Westlake Village, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Raul Silvestre
Headquarters
2629 Townsgate Road, Westlake Village, CA, US
Description

Rebus Holdings, Inc. focuses on the research and development of precision therapeutics for the treatment of cancer. Its lead asset is RT-AR001, an adenosine receptor antagonist for tumor infiltration and enhanced outcomes when administered intra-tumorally. The company was founded in 2003 and is based in Westlake Village, California.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for Rebus Holdings, Inc., and the rating behind it. RBSH last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Rebus Holdings, Inc.. Starting points for Rebus Holdings, Inc.: EPS -$0.03, beta 10.00 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Rebus Holdings, Inc.. Rebus Holdings, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Rebus Holdings, Inc.. Trailing twelve-month EPS for Rebus Holdings, Inc. stands at -$0.03. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Rebus Holdings, Inc.. Rebus Holdings, Inc. has reported as a listed company since 2009. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Rebus Holdings, Inc. valued side by side against its closest peers. Rebus Holdings, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold Rebus Holdings, Inc., and how their positions are changing. At a $3,213 market value, institutional positions materially move Rebus Holdings, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by Rebus Holdings, Inc. executives and directors. Shares of Rebus Holdings, Inc. have traded between $0.0001 and $0.0001 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Rebus Holdings, Inc.. Rebus Holdings, Inc. is a $3,213 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Rebus Holdings, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Rebus Holdings, Inc.. Coverage tracks Rebus Holdings, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Peer companies

  • ANTH — Anthera Pharmaceuticals, Inc.
  • CMRA — Comera Life Sciences Holdings, Inc.
  • FPMI — FluoroPharma Medical, Inc.
  • GBIM — GlobeImmune, Inc.
  • NLVVF — New Leaf Ventures Inc
  • NTII — Neurobiological Technologies, Inc.
  • PZRXQ — PhaseRx, Inc.
  • SNNAQ — Sienna Biopharmaceuticals, Inc.

More Biotechnology companies

  • CVKD — Cadrenal Therapeutics, Inc. Common Stock
  • CVM — CEL-SCI Corporation
  • CYCN — Cyclerion Therapeutics, Inc.
  • CYDY — CytoDyn Inc.
  • CYP.AX — Cynata Therapeutics Limited
  • CYTK — Cytokinetics, Incorporated
  • CYV.AX — Ceryvyn Therapeutics Ltd
  • CYYNF — Cynata Therapeutics Limited
  • DARE — Daré Bioscience, Inc.
  • CABA — Cabaletta Bio, Inc.
  • CADL — Candel Therapeutics, Inc.
  • CAI — Caris Life Sciences, Inc.

News

Latest Market News